Larimar Therapeutics to launch nomlabofusp in 2026, targeting $500mln revenue.

• Larimar Therapeutics is developing nomlabofusp, a planned product candidate. • Company to focus on digital data collection for nomlabofusp clinical trials. • Plans to submit a BLA and seek accelerated approval or access. • Time to launch and market expected to be significant. • Overall development plans and milestones outlined in the presentation.